CA
RPRX icon

CoreCap Advisors’s Royalty Pharma RPRX Stock Holding History

CoreCap Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1K Buy
876
+413
+89% +$21.5K ﹤0.01% 1414
2026
Q1 		$22.2K Buy
463
+400
+635% +$17.5K ﹤0.01% 1624
2025
Q4 		$2.43K Buy
+63
New +$2.4K ﹤0.01% 2430
2024
Q3 		– Sell
-73
Closed -$1.93K – 2727
2024
Q2 		$1.93K Buy
+73
New +$2.02K ﹤0.01% 1326

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's RPRX Position: Q2 2026 in Review

CoreCap Advisors increased its Royalty Pharma (RPRX) stake by 89% in Q2 2026, buying an estimated $21.5K and bringing the position to 876 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1414.

CoreCap Advisors first reported a position in RPRX in Q2 2024 and has held it in 4 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • CoreCap Advisors held 876 shares of Royalty Pharma worth $49.1K as of Q2 2026.
  • CoreCap Advisors bought 413 Royalty Pharma shares in Q2 2026, an estimated $21.5K.
  • Royalty Pharma made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1414 holding.
  • CoreCap Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 4 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.